Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 09/29/21
Kintara Announces Closing of $15.0 million Offering Priced at a Premium to MarketPRNewsWire • 09/28/21
Kintara announces $15M common stock and warrants offering priced at premium to marketProactive Investors • 09/24/21
Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to MarketPRNewsWire • 09/24/21
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM PatientsPRNewsWire • 09/22/21
Kintara Therapeutics says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme now activated in 26 US sitesProactive Investors • 08/17/21
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for GlioblastomaPRNewsWire • 08/17/21
Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021PRNewsWire • 08/12/21
Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021PRNewsWire • 08/04/21
Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083Benzinga • 07/01/21
Kintara Therapeutics reports topline results from Phase 2 clinical study of VAL-083 for recurrent GBMProactive Investors • 07/01/21
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBMPRNewsWire • 07/01/21
Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for glioblastoma multiformeProactive Investors • 06/03/21
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain TumorsPRNewsWire • 06/03/21
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021PRNewsWire • 06/02/21